Mission Earns MJFF Grant to Develop Familial Parkinson’s Treatment

Mission Earns MJFF Grant to Develop Familial Parkinson’s Treatment

309489

Mission Earns MJFF Grant to Develop Familial Parkinson’s Treatment

Mission Therapeutics has been awarded a Therapeutic Pipeline Program grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance development of its USP30 deubiquitylating enzyme (DUB) inhibitors for the treatment of familial Parkinson’s disease. The grant, worth about $500,000, will be used to test these inhibitors in animals that model the disease, and to support preclinical selection of candidates for clinical trials. “Receiving funding from the Michael J. Fox Foundation is a great accolade, recognizing the importance of USP30…

You must be logged in to read/download the full post.